Pakistan Medicine Shortage: Pricing Delays Trigger Healthcare Crisis

The Economics of Empty Pharmacy Shelves

Pakistan’s pharmaceutical sector is buckling under a supply chain crisis, as regulatory delays in adjusting medicine prices force manufacturers to halt production. According to the Drug Regulatory Authority of Pakistan (DRAP) and industry representatives, the math no longer works: when retail prices are frozen while inflation and currency devaluation climb, producing essential medication becomes financially unsustainable.

The Price-Control Deadlock

The shortage is rooted in a collision between government price controls and the soaring costs of imported Active Pharmaceutical Ingredients (APIs). As the Pakistani rupee weakened against the U.S. dollar, the cost of importing raw materials spiked. When production costs eclipse the government-mandated retail price, companies simply stop manufacturing to avoid operating at a loss. The result is a widening gap on pharmacy shelves, hitting everything from basic antibiotics to specialized chronic treatments.

A Dangerous Rise in Counterfeits

The scarcity of life-saving drugs has crippled public healthcare access. Major hospitals report that patients are struggling to source critical medications, including opioid-based painkillers essential for surgical procedures and cancer care. As shelves sit empty, desperate patients are turning to the unregulated market. Health advocates warn that this vacuum is being filled by counterfeit or substandard medications.

The Trap of Import Dependence

This reliance leaves the sector exposed to global supply chain shocks and currency volatility. While discussions regarding the China-Pakistan Economic Corridor (CPEC) 2.0 point toward localized API manufacturing as a solution, analysts argue the transition requires significant long-term capital and a more stable regulatory environment.

Drivers of the Current Crisis

• Currency Devaluation: The rising cost of importing raw materials has outpaced the government’s speed in adjusting MRPs.
• Regulatory Lag: Delays within the DRAP pricing committee process have historically hindered the industry’s ability to respond to economic shifts.
• Supply Chain Vulnerability: Over-reliance on international suppliers for APIs leaves local manufacturers with little control over production costs.
• Market Risks: Shortages have inadvertently increased the circulation of illicit and counterfeit drugs, threatening public health.

As the government evaluates new pricing policies, the stability of the supply chain depends on finding a balance between affordable healthcare for citizens and the commercial viability of local manufacturers. Future policy shifts will likely focus on streamlining the price-adjustment process to prevent the sudden disappearance of essential medicines from the market.